Vital

Peptides

CJC-1295 Ipamorelin Dosage Chart: Blend Units, Each vs Total

CJC-1295 ipamorelin dosage questions answered with facts: neither compound is FDA-approved, what a 5 mg / 5 mg vial holds, how a blend draw splits into each component, the each vs total math error, and DAC vs no DAC.

Last reviewed

The Vital angle

Vital's stack builder takes the mass of each component, the water volume, and your prescriber's draw, then shows how much of each component that draw delivers and how many draws the vial holds. A dose logged from a stack keeps the amount of each component, with the injection site, lot number, expiration date, and symptoms.

CJC-1295 ipamorelin dosage: the short answer

There is no approved CJC-1295 ipamorelin dosage. Neither CJC-1295 nor ipamorelin is an FDA-approved drug, no published trial has tested the blend, and no label gives a dose. The FDA lists serious adverse events for CJC-1295, including a faster heart rate and a reaction that widens blood vessels. For ipamorelin, the FDA says it found no safety data for injection under the skin.

The math question has a clear answer. A vial labeled "CJC-1295 / Ipamorelin 5 mg / 5 mg" holds 5 mg of each compound, or 10 mg in total. Each draw from a blend vial delivers both compounds at a fixed ratio. If you mix up "each" and "total," every number you calculate is wrong by a factor of 2.

This guide explains the status, the blend math, and the difference between CJC-1295 with and without DAC. It uses hypothetical round numbers only. It does not recommend a dose, a schedule, or a cycle. Ask the prescriber who gave you the vial.

What CJC-1295 and ipamorelin are

The two compounds act on the growth hormone system in different ways:

  • CJC-1295 is a lab-made analog of growth hormone-releasing hormone (GHRH). It tells the pituitary gland to release growth hormone. Tesamorelin, sold as Egrifta, is a different GHRH analog that is FDA-approved for one narrow use. See tesamorelin dosage units.
  • Ipamorelin acts on the ghrelin receptor, which is a second signal for growth hormone release.

Sellers combine them on the theory that two signals give a larger growth hormone pulse. No published human trial has tested that claim for the blend.

Regulatory status and safety findings

CJC-1295 Ipamorelin
FDA-approved drug No No
FDA compounding page Nominated, then withdrawn Category 2 for outsourcing facilities since September 29, 2023, and in the withdrawn table
FDA safety notes Possible immune reactions; serious adverse events including increased heart rate and a systemic vasodilatory reaction Possible immune reactions; unnatural amino acids; serious adverse events, including death, in an IV study
Published human trials Small studies of the DAC version in healthy adults One phase 2 IV trial after bowel surgery

In October 2024, the FDA wrote a briefing about ipamorelin for its compounding advisory committee. It describes a phase 2 trial that enrolled 117 adults after abdominal surgery, and 114 of them got ipamorelin or placebo by IV. Two people on ipamorelin died after complications of bowel surgery, and the FDA said it was unclear whether the deaths were related to the drug. The FDA also noted more hypokalemia and hyperglycemia on ipamorelin, and it found no safety data for injection under the skin.

The same briefing quotes clinic offers of a "CJC-1295/ipamorelin (lyo) 6/6 mg vial." Blends of this type are common, but they are not approved products.

CJC-1295 no DAC vs DAC

"DAC" means drug affinity complex. It is a chemical group that lets the peptide bind albumin in the blood, so it stays in the body much longer.

  • CJC-1295 with DAC. In a 2006 study in healthy adults, published in the Journal of Clinical Endocrinology and Metabolism, the estimated half-life was 5.8 to 8.1 days. One injection raised growth hormone for 6 days or more and IGF-1 for 9 to 11 days.
  • CJC-1295 without DAC. This is also called modified GRF (1-29). The FDA briefing calls it "tetra-substituted GRF (1-29)." It lasts a much shorter time, and published human data on it are scarce.

Most "CJC-1295 / ipamorelin" blends use the no-DAC form. The two forms are different compounds with different half-lives. Check which one the label names, and do not swap one for the other. The peptide half-life guide explains why half-life matters for timing.

Each vs total: the blend math error

A blend label can show the mass in two ways:

  • Each: "5 mg / 5 mg" means 5 mg of CJC-1295 plus 5 mg of ipamorelin, 10 mg in total.
  • Total: "10 mg blend" can mean 10 mg in total, which could be 5 mg plus 5 mg.

The error happens when you read one as the other. The numbers below are hypothetical and show the math only.

Label What you think What the vial holds Result in each draw
5 mg / 5 mg 5 mg in total 5 mg of each Twice the amount you calculated
10 mg blend (total) 10 mg of each 5 mg of each Half the amount you calculated

If the label is not clear, ask the pharmacy for the mass of each component and check the certificate of analysis. See how to read a peptide vial label and peptide catalog source checks.

Blend dosage chart: a 5 mg / 5 mg vial in units

The formula for each component in a blend is:

Amount of a component = mg of that component in the vial × (draw in mL ÷ mL of water)

On a U-100 syringe, 1 unit is 0.01 mL. The chart uses a hypothetical 5 mg / 5 mg vial. The draws are round numbers for the math. They are not doses.

Water added Draw Volume CJC-1295 in the draw Ipamorelin in the draw Total Draws per vial
2 mL 5 units 0.05 mL 125 mcg 125 mcg 250 mcg 40
2 mL 10 units 0.10 mL 250 mcg 250 mcg 500 mcg 20
2 mL 20 units 0.20 mL 500 mcg 500 mcg 1,000 mcg 10
3 mL 10 units 0.10 mL 167 mcg 167 mcg 333 mcg 30
3 mL 20 units 0.20 mL 333 mcg 333 mcg 667 mcg 15

Three points follow from the chart:

  1. You cannot change the amount of one component without changing the other. The ratio is fixed when the vial is made.
  2. More water gives less of each component per unit. A unit count from someone else's vial means nothing unless the water volume and the masses are the same.
  3. A blend with unequal masses, such as 2 mg / 5 mg, delivers a different amount of each in the same draw. Do the math for each component.

Confirm every draw with your prescriber or pharmacist, in mL and in units, before you inject. The free peptide calculator shows concentration and doses per vial. For mixing steps, see how to reconstitute peptides with BAC water.

Tracking a blend in Vital

Vital treats a blend as a stack. In the stack builder, you enter each component with its own mass in mg or mcg, the water volume, and the draw your prescriber gave you. Vital then shows how much of each component that draw delivers, using the formula above, and how many draws the vial holds. It does not suggest a draw.

When you log a dose from a stack, the log keeps the amount of each component, so your record says "250 mcg CJC-1295 and 250 mcg ipamorelin," not only "10 units." The dose log also keeps the injection site, the lot number, the expiration date, and any symptoms with a severity. The Vital peptide directory has separate profiles for CJC-1295, CJC-1295 DAC, and ipamorelin, each with its FDA status and evidence level. For other blends, see the Glow peptide blend dosage guide and the KLOW blend guide. For a comparison of trackers, see the best peptide tracker app.

Warning signs and when to get care

Get emergency care for chest pain, trouble breathing, fainting, or swelling of the face, lips, tongue, or throat. Get medical care soon for any of these signs:

  • A racing or pounding heartbeat, or flushing with dizziness.
  • New thirst, frequent urination, or blurred vision, which can be signs of high blood sugar.
  • Swelling in the hands or feet, or numbness and tingling in the hand.
  • A hot, red, spreading, or very painful injection site, or fever after an injection.

If you think you injected much more than intended, call your clinician or Poison Help at 1-800-222-1222. If you also take a GLP-1 medicine, read stacking peptides with a GLP-1, because growth hormone signals can affect blood sugar.


Egrifta® (tesamorelin) is a trademark of Theratechnologies. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Reading 5 mg / 5 mg as the total

    A 5 mg / 5 mg label means 5 mg of each compound. Treating it as 5 mg in total makes every draw deliver twice the amount you calculated.

  • Swapping CJC-1295 DAC and no-DAC

    The DAC form had an estimated half-life of 5.8 to 8.1 days in a 2006 study. The no-DAC form lasts a much shorter time, so the two are not interchangeable.

  • Ipamorelin safety data

    The FDA found no safety data for ipamorelin by subcutaneous injection, and an IV trial reported hypokalemia, hyperglycemia, and two deaths of unclear relation.

  • CJC-1295 adverse events

    The FDA lists serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.

  • Unit counts from another person's vial

    The amount of each component per unit depends on the masses and the water volume. A unit count only transfers if all three are the same.

Frequently asked questions

  • There is no approved dosage. Neither compound is an FDA-approved drug, no published trial has tested the blend, and the FDA found no safety data for ipamorelin by subcutaneous injection. Ask the prescriber who gave you the vial.

  • It means 5 mg of CJC-1295 plus 5 mg of ipamorelin, 10 mg in total. If you treat it as 5 mg in total, each draw delivers twice the amount you calculated.

  • Math example with hypothetical numbers: a 5 mg / 5 mg vial with 2 mL of water gives 250 mcg of each compound in 10 units (0.10 mL). With 3 mL of water, 10 units gives about 167 mcg of each. Confirm any draw with your prescriber or pharmacist.

  • DAC lets the peptide bind albumin, so it lasts longer. A 2006 study estimated a half-life of 5.8 to 8.1 days for the DAC form. The no-DAC form, also called modified GRF (1-29), lasts a much shorter time.

  • No. Neither compound is FDA-approved. The FDA compounding page lists safety concerns for both, and ipamorelin acetate is in Category 2 for outsourcing facilities.

  • No. The ratio is fixed when the vial is made, so each draw delivers both compounds in that ratio. A unit count changes both amounts together. Your prescriber decides which product and amount apply to you.

Sources

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  2. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-related bulk drug substances · U.S. Food and Drug Administration
  3. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · NIH / PubMed (Journal of Clinical Endocrinology and Metabolism, 2006)
  4. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074) · ClinicalTrials.gov, U.S. National Library of Medicine

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.